Table 1.
Cancer type | Low expression level | High expression level |
---|---|---|
AML | TRIM62 [23] | / |
HCC | TRIM26 [24], TRIM28, TRIM37, TRIM45, TRIM59 [25], TRIM59 [26] | TRIM11 [27, 28], TRIM16 [29], TRIM24 [30], TRIM25 [31], TRIM27 [32], TRIM31 [33], TRIM37 [34], TRIM50 [26], TRIM3, TRIM5, TRIM21, TRIM27, TRIM32, TRIM44, TRIM47, TRIM72 [35] |
RCC | / | TRIM27 [36], TRIM37 [37], TRIM44 [38] |
UCB | / | TRIM65 [39] |
GBC | TRIM31 [40] | |
PTC | / | TRIM14 [41] |
HEC | / | TRIM44 [42] |
TGCT | / | TRIM44 [43] |
NPC | / | TRIM11 [44] |
OC | TRIM50 [45] | TRIM59 [46] |
CRC | TRIM1, TRIM2, TRIM6, TRIM13, TRIM26, TRIM35,TRIM55 [47], TRIM58 [48] | TRIM23 [49], TRIM24 [50], TRIM27 [51], TRIM47 [47], TRIM39 [52] |
Pancreatic carcinoma | TRIM36 [53], TRIM50 [54] | TRIM11 [55], TRIM15 [56], TRIM37 [57], TRIM47 [58], TRIM59 [59] |
Gastric carcinoma | TRIM3 [60], TRIM21 [61] | TRIM14 [62], TRIM15 [63], TRIM23 [64], TRIM29 [65], TRIM32 [66, 67], TRIM44 [68], TRIM47 [69], TRIM54 [70] |
Glioblastoma | TRIM8 [71], TRIM16 [72], TRIM17 [73] | TRIM14 [74], TRIM21 [75], TRIM28 [76] |
Breast carcinoma | TRIM16 [72], TRIM29 [77], TRIM31 [78], TRIM35 [79] | TRIM3 [80], TRIM39 [81], TRIM44 [82, 83], TRIM47 [84], TRIM59 [85, 86], TRIM62 [87] |
Lung carcinoma | TRIM28 [88], TRIMs56 [89] | TRIM11 [90], TRIM15 [91, 92], TRIM23 [93], TRIM35 [94], TRIM46 [95], TRIM66 [96] |
melanoma | / | TRIM27 [97] |
Squamous carcinoma | / | TRIM28 [98] |
Osteosarcoma | TRIM22 [99] | TRIM7 [100] |
The expression levels of different TRIM family proteins positively related to the adverse prognostic in various types of clinical tumor tissue samples. The adverse prognostic refers to the lower survivability of the diagnosis
AML: acute myelocytic leukemia, HCC: hepatocellular carcinoma, RCC renal cell carcinoma, UCB: urothelium carcinoma, PTC: papillary thyroid cancer, LC lung cancer, HEC: human esophageal cancer, LUAD lung adenocarcinoma, TGCT testicular germ cell tumors, NPC nasopharyngeal carcinoma; OC ovarian cancer, CRC colorectal cancer